FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282919847> ?p ?o ?g. }

• W4282919847 endingPage "511.e10" @default.
• W4282919847 startingPage "511.e1" @default.
• W4282919847 abstract "Voriconazole (VCZ) was one of the first mold-active triazoles available; however, its current use among high-risk hematology populations is unknown as the uptake of posaconazole (PCZ) and isavuconazole (ISZ) increases. We evaluated the usage and therapeutic level attainment of VCZ in hematopoietic cell transplantation (HCT) and chimeric antigen receptor T cell (CAR-T) therapy patients at our cancer center. Electronic medical records for all adult HCT or CAR-T patients with an order for VCZ, PCZ, or ISV between January 1, 2018, and June 30, 2020, were extracted. Clinical characteristics, VCZ indication, trough VCZ levels, and frequency of VCZ initiation from 6 months before to 6 months after HCT/CAR-T infusion in consecutive HCT/CAR-T recipients within the study period (infusion between July 1, 2018, and January 1, 2020) were assessed. The association between relevant clinical characteristics and the attainment of subtherapeutic or supratherapeutic levels was also evaluated. Of 468 patients prescribed mold-active triazoles, 256 (54.7%) were prescribed VCZ, 324 (69.2%) PCZ, and 60 (12.8%) ISZ; 152/468 (32.5%) treatment regimens were sequentially modified to alternate mold-active triazoles. Among consecutive HCT and CAR-T recipients at our center, evaluated 6 months pre- or post- HCT/ CAR-T, VCZ was commonly initiated before or after allogeneic HCT (102/381, 26.8%), with most use in the first 30 days after stem cell infusion (40/381, 10.5%); VCZ use was less common in autologous HCT (13/276, 4.7%) and CAR-T (10/153, 6.5%). Of 223 VCZ orders that met inclusion for analysis, indications included empiric treatment in 108/223 (48.4%), directed therapy in 25/223 (11.2%), primary prophylaxis in 69/223 (30.9%) and secondary prophylaxis in 21/223 (9.4%). Of 223 eligible VCZ patients, 144 (64.6%) had at least 1 VCZ level measured during the study period; 75/144 (52.1%) had a therapeutic VCZ level (1.0-5.5 mg/L) at the first measurement (median 2.8mg/L [range 0.1-13.5]) at a median of 6 days of therapy, with 26.4% subtherapeutic and 21.5% supratherapeutic; 46/88 (52.3%) were therapeutic at the second measurement (2.1mg/L [0.1-9.9]) at a median of 17 days of therapy; and 33/48 (68.8%) at the third (2.3mg/L [0.1-7.7]) at a median of 29 days. In multivariable analysis of factors associated with sub- or supratherapeutic levels (body mass index ≥30, concurrent omeprazole use, concurrent letermovir use, indication for VCZ, history/timeframe of HCT), the only significant association was lower odds of a supratherapeutic VCZ level among those undergoing HCT within the previous 30 days compared to those without a history of HCT. VCZ continues to remain an important option in the treatment and prevention of invasive fungal infections in an era when alternative oral mold-active triazoles are available. In spite of long-standing experience with VCZ prescribing, therapeutic level attainment remains a challenge." @default.
• W4282919847 created "2022-06-16" @default.
• W4282919847 creator A5000958441 @default.
• W4282919847 creator A5021734413 @default.
• W4282919847 creator A5022401878 @default.
• W4282919847 creator A5037683678 @default.
• W4282919847 creator A5042065593 @default.
• W4282919847 creator A5057612788 @default.
• W4282919847 creator A5057782869 @default.
• W4282919847 creator A5066166630 @default.
• W4282919847 creator A5068568592 @default.
• W4282919847 creator A5070154371 @default.
• W4282919847 creator A5074618125 @default.
• W4282919847 creator A5075743029 @default.
• W4282919847 creator A5085214892 @default.
• W4282919847 creator A5091592847 @default.
• W4282919847 date "2022-08-01" @default.
• W4282919847 modified "2023-10-18" @default.
• W4282919847 title "Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center" @default.
• W4282919847 cites W1831954428 @default.
• W4282919847 cites W1974401164 @default.
• W4282919847 cites W1980215726 @default.
• W4282919847 cites W1986071890 @default.
• W4282919847 cites W1988385266 @default.
• W4282919847 cites W1989345554 @default.
• W4282919847 cites W1991663710 @default.
• W4282919847 cites W2013416277 @default.
• W4282919847 cites W2018076747 @default.
• W4282919847 cites W2035265444 @default.
• W4282919847 cites W2036323185 @default.
• W4282919847 cites W2042257719 @default.
• W4282919847 cites W2097656114 @default.
• W4282919847 cites W2108627308 @default.
• W4282919847 cites W2114661666 @default.
• W4282919847 cites W2134732827 @default.
• W4282919847 cites W2134802281 @default.
• W4282919847 cites W2152197116 @default.
• W4282919847 cites W2161457899 @default.
• W4282919847 cites W2162857158 @default.
• W4282919847 cites W2175067891 @default.
• W4282919847 cites W2189861011 @default.
• W4282919847 cites W2196792053 @default.
• W4282919847 cites W2276581170 @default.
• W4282919847 cites W2393833631 @default.
• W4282919847 cites W2461860618 @default.
• W4282919847 cites W2470291098 @default.
• W4282919847 cites W2562778159 @default.
• W4282919847 cites W2563079954 @default.
• W4282919847 cites W2793884909 @default.
• W4282919847 cites W2890837116 @default.
• W4282919847 cites W2916176185 @default.
• W4282919847 cites W2937526073 @default.
• W4282919847 cites W2975697634 @default.
• W4282919847 cites W2976188860 @default.
• W4282919847 cites W2992673867 @default.
• W4282919847 cites W3007584875 @default.
• W4282919847 cites W3008070365 @default.
• W4282919847 cites W3090336596 @default.
• W4282919847 cites W3103430162 @default.
• W4282919847 cites W3127013644 @default.
• W4282919847 cites W3165441575 @default.
• W4282919847 cites W4200111432 @default.
• W4282919847 doi "https://doi.org/10.1016/j.jtct.2022.05.030" @default.
• W4282919847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35623614" @default.
• W4282919847 hasPublicationYear "2022" @default.
• W4282919847 type Work @default.
• W4282919847 citedByCount "4" @default.
• W4282919847 countsByYear W42829198472022 @default.
• W4282919847 countsByYear W42829198472023 @default.
• W4282919847 crossrefType "journal-article" @default.
• W4282919847 hasAuthorship W4282919847A5000958441 @default.
• W4282919847 hasAuthorship W4282919847A5021734413 @default.
• W4282919847 hasAuthorship W4282919847A5022401878 @default.
• W4282919847 hasAuthorship W4282919847A5037683678 @default.
• W4282919847 hasAuthorship W4282919847A5042065593 @default.
• W4282919847 hasAuthorship W4282919847A5057612788 @default.
• W4282919847 hasAuthorship W4282919847A5057782869 @default.
• W4282919847 hasAuthorship W4282919847A5066166630 @default.
• W4282919847 hasAuthorship W4282919847A5068568592 @default.
• W4282919847 hasAuthorship W4282919847A5070154371 @default.
• W4282919847 hasAuthorship W4282919847A5074618125 @default.
• W4282919847 hasAuthorship W4282919847A5075743029 @default.
• W4282919847 hasAuthorship W4282919847A5085214892 @default.
• W4282919847 hasAuthorship W4282919847A5091592847 @default.
• W4282919847 hasBestOaLocation W42829198471 @default.
• W4282919847 hasConcept C109159458 @default.
• W4282919847 hasConcept C126322002 @default.
• W4282919847 hasConcept C143998085 @default.
• W4282919847 hasConcept C16005928 @default.
• W4282919847 hasConcept C2777408962 @default.
• W4282919847 hasConcept C2779548794 @default.
• W4282919847 hasConcept C2780073493 @default.
• W4282919847 hasConcept C2780690907 @default.
• W4282919847 hasConcept C28328180 @default.
• W4282919847 hasConcept C2911091166 @default.
• W4282919847 hasConcept C2993713153 @default.
• W4282919847 hasConcept C54355233 @default.
• W4282919847 hasConcept C71924100 @default.

• next